A therapeutically targetable mechanism of BCR-ABL - Independent imatinib resistance in chronic myeloid leukemia

Science Translational Medicine

Volumn 6, Issue 252, 2014, Pages

  Ma, Leyuan ^a   Shan, Yi ^a   Bai, Robert ^a   Xue, Liting ^a   Eide, Christopher A ^b   Ou, Jianhong ^a   Zhu, Lihua J ^a   Hutchinson, Lloyd ^a   Cerny, Jan ^a   Khoury, Hanna Jean ^c   Sheng, Zhi ^d,e   Druker, Brian J ^b   Li, Shaoguang ^a   Green, Michael R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^e VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE C; PROTEIN KINASE C ETA; RAF PROTEIN; SHORT HAIRPIN RNA; TRAMETINIB; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; IC50; LEUKEMIA CELL; MOUSE; NONHUMAN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOSPHORYLATION; SURVIVAL ANALYSIS; TUMOR CELL LINE; TUMOR GENE;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUSION PROTEINS, BCR-ABL; GENE KNOCKDOWN TECHNIQUES; GENES, NEOPLASM; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RAF KINASES; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84907292003     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009073     Document Type: Article

References (69)

1. S. Faderl, M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, H. M. Kantarjian, The biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164-172 (1999).
2. M. W. Deininger, J. M. Goldman, J. V. Melo, The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 (2000).
3. R. Kurzrock, H. M. Kantarjian, B. J. Druker, M. Talpaz, Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138, 819-830 (2003).
4. J. Colicelli, ABL tyrosine kinases: Evolution of function, regulation, and specificity. Sci. Signal. 3, re6 (2010).
5. L. S. Steelman, S. C. Pohnert, J. G. Shelton, R. A. Franklin, F. E. Bertrand, J. A. McCubrey, JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218 (2004).
6. X. An, A. K. Tiwari, Y. Sun, P. R. Ding, C. R. Ashby Jr., Z. S. Chen, BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk. Res. 34, 1255-1268 (2010).
7. N. von Bubnoff, C. Peschel, J. Duyster, Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): A targeted oncoprotein strikes back. Leukemia 17, 829-838 (2003).
8. A. Quintás-Cardama, H. M. Kantarjian, J. E. Cortes, Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16, 122-131 (2009).
9. E. Jabbour, H. Kantarjian, D. Jones, M. Talpaz, N. Bekele, S. O 'Brien, X. Zhou, R. Luthra, G. Garcia-Manero, F. Giles, M. B. Rios, S. Verstovsek, J. Cortes, Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20, 1767-1773 (2006).
10. N. P. Shah, J. M. Nicoll, B. Nagar, M. E. Gorre, R. L. Paquette, J. Kuriyan, C. L. Sawyers, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
11. E. Weisberg, P. W. Manley, S. W. Cowan-Jacob, A. Hochhaus, J. D. Griffin, Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7, 345-356 (2007).
12. N. J. Donato, J. Y. Wu, J. Stapley, H. Lin, R. Arlinghaus, B. B. Aggarwal, S. Shishodia, M. Albitar, K. Hayes, H. Kantarjian, M. Talpaz, Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64, 672-677 (2004).
13. J. S. Khorashad, M. Anand, D. Marin, S. Saunders, T. Al-Jabary, A. Iqbal, S. Margerison, J. V. Melo, J. M. Goldman, J. F. Apperley, J. Kaeda, The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20, 658-663 (2006).
14. M. Dean, T. Fojo, S. Bates, Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
15. S. M. Graham, H. G. Jørgensen, E. Allan, C. Pearson, M. J. Alcorn, L. Richmond, T. L. Holyoake, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
16. A. S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. W. Deininger, B. J. Druker, Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396-409 (2011).
17. A. Hamilton, G. V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E. K. Allan, F. E. Nicolini, C. Müller-Tidow, R. Bhatia, V. G. Brunton, S. Koschmieder, T. L. Holyoake, Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501-1510 (2012).
18. L. C. Andersson, K. Nilsson, C. G. Gahmberg, K562-A human erythroleukemic cell line. Int. J. Cancer 23, 143-147 (1979).
19. J. M. Silva, M. Z. Li, K. Chang, W. Ge, M. C. Golding, R. J. Rickles, D. Siolas, G. Hu, P. J. Paddison, M. R. Schlabach, N. Sheth, J. Bradshaw, J. Burchard, A. Kulkarni, G. Cavet, R. Sachidanandam, W. R. McCombie, M. A. Cleary, S. J. Elledge, G. J. Hannon, Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37, 1281-1288 (2005).
20. T. Ohkubo, T. Kamamoto, K. Kita, A. Hiraoka, Y. Yoshida, H. Uchino, A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis. Leuk. Res. 9, 921-926 (1985).
21. bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
22. S. Li, R. L. Ilaria Jr., R. P. Million, G. Q. Daley, R. A. Van Etten, The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399-1412 (1999).
23. H. Quentmeier, S. Eberth, J. Romani, M. Zaborski, H. G. Drexler, BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J. Hematol. Oncol. 4, 6 (2011).
24. N. P. Shah, C. Tran, F. Y. Lee, P. Chen, D. Norris, C. L. Sawyers, Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399 -401 (2004).
25. N. J. Donato, J. Y. Wu, J. Stapley, G. Gallick, H. Lin, R. Arlinghaus, M. Talpaz, BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690-698 (2003).
26. J. ten Hoeve, R. B. Arlinghaus, J. Q. Guo, N. Heisterkamp, J. Groffen, Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 84, 1731-1736 (1994).
27. T. Takahashi, H. Ueno, M. Shibuya, VEGF activates protein kinase C-dependent, but Rasindependent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221-2230 (1999).
28. Y. Ueda, S. Hirai, S. Osada, A. Suzuki, K. Mizuno, S. Ohno, Protein kinase C d activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem. 271, 23512-23519 (1996).
29. R. M. Uht, S. Amos, P. M. Martin, A. E. Riggan, I. M. Hussaini, The protein kinase C-h isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene 26, 2885-2893 (2007).
30. A. Aderem, The MARCKS brothers: A family of protein kinase C substrates. Cell 71, 713-716 (1992).
31. R. Chakrabarti, J. Hwang, M. Andres Blanco, Y. Wei, M. Lukačišin, R. A. Romano, K. Smalley, S. Liu, Q. Yang, T. Ibrahim, L. Mercatali, D. Amadori, B. G. Haffty, S. Sinha, Y. Kang, Elf5 inhibits the epithelial - mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat. Cell Biol. 14, 1212-1222 (2012).
32. R. Escamilla-Hernandez, R. Chakrabarti, R. A. Romano, K. Smalley, Q. Zhu, W. Lai, M. S. Halfon, M. J. Buck, S. Sinha, Genome-wide search identifies Ccnd2 as a direct transcriptional target of Elf5 in mouse mammary gland. BMC Mol. Biol. 11, 68 (2010).
33. M. Kalyuga, D. Gallego-Ortega, H. J. Lee, D. L. Roden, M. J. Cowley, C. E. Caldon, A. Stone, S. L. Allerdice, F. Valdes-Mora, R. Launchbury, A. L. Statham, N. Armstrong, M. C. Alles, A. Young, A. Egger, W. Au, C. L. Piggin, C. J. Evans, A. Ledger, T. Brummer, S. R.Oakes, W. Kaplan, J. M. Gee, R. I. Nicholson, R. L. Sutherland, A. Swarbrick, M. J. Naylor, S. J. Clark, J. S. Carroll, C. J. Ormandy, ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLOS Biol. 10, e1001461 (2012).
34. C. Wellbrock, M. Karasarides, R. Marais, The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885 (2004).
35. M. P. Carroll, W. S. May, Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells. J. Biol. Chem. 269, 1249-1256 (1994).
36. W. Kolch, G. Heidecker, G. Kochs, R. Hummel, H. Vahidi, H. Mischak, G. Finkenzeller, D. Marmé, U. R. Rapp, Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature 364, 249-252 (1993).
37. T. Suzuki, B. C. Elias, A. Seth, L. Shen, J. R. Turner, F. Giorgianni, D. Desiderio, R. Guntaka, R. Rao, PKCη regulates occludin phosphorylation and epithelial tight junction integrity. Proc. Nat. Acad. Sci. U.S.A. 106, 61-66 (2009).
38. H. Cai, U. Smola, V. Wixler, I. Eisenmann-Tappe, M. T. Diaz-Meco, J. Moscat, U. Rapp, G. M. Cooper, Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol. Cell. Biol. 17, 732-741 (1997).
39. D. C. Schönwasser, R. M. Marais, C. J. Marshall, P. J. Parker, Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol. 18, 790-798 (1998).
40. O. Sözeri, K. Vollmer, M. Liyanage, D. Frith, G. Kour, G. E. Mark III, S. Stabel, Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene 7, 2259 - 2262 (1992).
41. S. J. Neering, T. Bushnell, S. Sozer, J. Ashton, R. M. Rossi, P. Y. Wang, D. R. Bell, D. Heinrich, A. Bottaro, C. T. Jordan, Leukemia stem cells in a genetically defined murine model of blastcrisis CML. Blood 110, 2578-2585 (2007).
42. B. Zhang, A. C. Strauss, S. Chu, M. Li, Y. Ho, K. D. Shiang, D. S. Snyder, C. S. Huettner, L. Shultz, T. Holyoake, R. Bhatia, Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427-442 (2010).
43. H. Zhang, C. Peng, Y. Hu, H. Li, Z. Sheng, Y. Chen, C. Sullivan, J. Cerny, L. Hutchinson, A. Higgins, P.Miron, X. Zhang, M. A. Brehm, D. Li,M. R. Green, S. Li, The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat. Genet. 44, 861-871 (2012).
44. L. Li, L. Wang, L. Li, Z. Wang, Y. Ho, T. McDonald, T. L. Holyoake, W. Chen, R. Bhatia, Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266-281 (2012).
45. X. Jiang, Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, A. Eaves, C. Eaves, Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21, 926-935 (2007).
46. N. A. Lobo, Y. Shimono, D. Qian, M. F. Clarke, The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23, 675-699 (2007).
47. R. Bhatia, M. Holtz, N. Niu, R. Gray, D. S. Snyder, C. L. Sawyers, D. A. Arber, M. L. Slovak, S. J. Forman, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
48. J. C. Chomel, M. L. Bonnet, N. Sorel, A. Bertrand, M. C. Meunier, S. Fichelson, M. Melkus, A. Bennaceur-Griscelli, F. Guilhot, A. G. Turhan, Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118, 3657-3660 (2011).
49. F. Pellicano, L. Mukherjee, T. L. Holyoake, Concise review: Cancer cells escape from oncogene addiction: Understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells 32, 1373-1379 (2014).
50. J. M. Gerber, J. L. Gucwa, D. Esopi, M. Gurel, M. C. Haffner, M. Vala, W. G. Nelson, R. J. Jones, S. Yegnasubramanian, Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget 4, 715-728 (2013).
51. T. Konuma, S. Nakamura, S. Miyagi, M. Negishi, T. Chiba, H. Oguro, J. Yuan, M. Mochizuki-Kashio, H. Ichikawa, H. Miyoshi, M. Vidal, A. Iwama, Forced expression of the histone demethylase Fbxl10 maintains self-renewing hematopoietic stem cells. Exp. Hematol. 39, 697-709.e5 (2011).
52. F. O. Bagger, N. Rapin, K. Theilgaard-Mönch, B. Kaczkowski, L. A. Thoren, J. Jendholm, O. Winther, B. T. Porse, HemaExplorer: A database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res. 41, D1034-D1039 (2013).
53. L. M. Packer, S. Rana, R. Hayward, T. O'Hare, C. A. Eide, A. Rebocho, S. Heidorn, M. S. Zabriskie, I. Niculescu-Duvaz, B. J. Druker, C. Springer, R. Marais, Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 20, 715-727 (2011).
54. C. I. Aceves-Luquero, A. Agarwal, J. L. Callejas-Valera, L. Arias-González, A. Esparís-Ogando, L. del Peso Ovalle, I. Bellón-Echeverria, M. A. de la Cruz-Morcillo, E. M. Galán Moya, I. Moreno Gimeno, J. C. Gómez, M. W. Deininger, A. Pandiella, R. Sánchez Prieto, ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: Implication for CML therapy. PLOS One 4, e6124 (2009).
55. J. Hentschel, I. Rubio, M. Eberhart, C. Hipler, J. Schiefner, K. Schubert, I. F. Loncarevic, U. Wittig, A. Baniahmad, F. von Eggeling, BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML. Int. J. Oncol. 39, 585-591 (2011).
56. T. Nambu, N. Araki, A. Nakagawa, A. Kuniyasu, T. Kawaguchi, A. Hamada, H. Saito, Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci. 101, 137-142 (2010).
57. J. S. Chang, R. Santhanam, R. Trotta, P. Neviani, A. M. Eiring, E. Briercheck, M. Ronchetti, D. C. Roy, B. Calabretta, M. A. Caligiuri, D. Perrotti, High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPα-driven myeloid differentiation. Blood 110, 994-1003 (2007).
58. + cells. Blood 103, 3167-3174 (2004).
59. D. Mizuchi, T. Kurosu, A. Kida, Z. H. Jin, A. Jin, A. Arai, O. Miura, BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem. Biophys. Res. Commun. 326, 645-651 (2005).
60. F. Pellicano, P. Simara, A. Sinclair, G. V. Helgason, M. Copland, S. Grant, T. L. Holyoake, The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia 25, 1159-1167 (2011).
61. J. Mullenders, R. Bernards, Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 28, 4409-4420 (2009).
62. D. Bruennert, A. Czibere, I. Bruns, R. Kronenwett, N. Gattermann, R. Haas, F. Neumann, Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 23, 983-985 (2009).
63. J. P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, W. Stock, C. L. Willman, S. Friend, P. S. Linsley, Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 103, 2794-2799 (2006).
64. J. Jing, J. Greshock, J. D. Holbrook, A. Gilmartin, X. Zhang, E. McNeil, T. Conway, C. Moy, S. Laquerre, K. Bachman, R. Wooster, Y. Degenhardt, Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol. Cancer Ther. 11, 720-729 (2012).
65. C. Gazin, N. Wajapeyee, S. Gobeil, C. M. Virbasius, M. R. Green, An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449, 1073-1077 (2007).
66. B. S. Carvalho, R. A. Irizarry, A framework for oligonucleotide microarray preprocessing. Bioinformatics 26, 2363-2367 (2010).
67. R. Ihaka, R. Gentleman, R: A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299-314 (1996).
68. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300 (1995).
69. B. K. Slinker, The statistics of synergism. J. Mol. Cell. Cardiol. 30, 723-731 (1998).